Formulations of histone deacetylase inhibitor and uses therof
View Patent ↗Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
1. A method of treating a hematologic cancer selected from: B-cell lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of Compound 1
or a pharmaceutically-acceptable salt thereof.
2. The method of claim 1 , further comprising administering bendamustine.
3. The method of claim 1 , further comprising administering doxorubicin.
4. The method of claim 1 , wherein the hematologic cancer is Hodgkin lymphoma.
5. The method of claim 1 , wherein the hematologic cancer is CLL.
6. The method of claim 1 , wherein the hematologic cancer is multiple myeloma.
7. A method of treating a sarcoma in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of Compound 1
or a pharmaceutically-acceptable salt thereof.
8. The method of claim 7 , further comprising administering doxorubicin.
9. A method of treating a cancer in an individual in need thereof, comprising administering to the individual:
(a) a therapeutically-effective amount of Compound 1
or a pharmaceutically-acceptable salt thereof, and
(b) an anti-cancer agent, selected from bendamustine, a proteasome inhibitor or doxorubicin.
10. The method of claim 9 , wherein the anti-cancer agent is bendamustine.
11. The method of claim 10 , wherein the cancer is a lymphoma.
12. The method of claim 9 , wherein the anti-cancer agent is a proteasome inhibitor.
13. The method of claim 12 , wherein the cancer is Hodgkin lymphoma, CLL, or Burkitt's lymphoma.
14. The method of claim 10 , wherein the cancer is multiple myeloma or Burkitt's lymphoma.
15. The method of claim 9 , wherein the anti-cancer agent is doxorubicin.
16. The method of claim 15 , wherein the cancer is non-Hodgkin's lymphoma or Burkitt's lymphoma.
17. The method of claim 1 , further comprising administering a proteasome inhibitor.